Ambien Hits Back at Roseanne: “Racism Is Not a Known Side Effect”

The just-fired TV host had blamed her sleeping pills for a bigoted tweet.

Kristin Callahan/ZUMA

Get your news from a source that’s not owned and controlled by oligarchs. Sign up for the free Mother Jones Daily.

The manufacturer of Ambien is pushing back against Roseanne Barr’s attempt to blame the drug for a racist tweet she published and deleted Tuesday. 

“People of all races, religions and nationalities work at Sanofi every day to improve the lives of people around the world,” Sanofi US, the company behind the commonly prescribed sleeping pill, said in a Wednesday statement. “While all pharmaceutical treatments have side effects, racism is not a known side effect of any Sanofi medication.”

The company was responding to another since deleted tweet Barr sent on Wednesday, where the TV star claimed “ambien tweeting” prompted her to liken Valerie Jarrett, a former senior adviser to Barack Obama who is black, to an ape. Just hours after that tweet gained attention on social media, ABC said it was canceling Roseanne for what it denounced as an “abhorrent” and “repugnant” statement by Barr.

The 2018 reboot of the popular sitcom had been attracting high ratings—even while some jokes drew controversy and as Barr kept up her well-established record of promoting baseless, right-wing conspiracy theories.

Despite Barr’s announcement that she would soon be leaving Twitter, along with a public apology she sent to Jarrett, Barr continued to retweet right-wing conspiracy theories about the former Obama adviser well into Wednesday evening. Other Barr retweets suggested ABC was wrong to cancel Roseanne and that Barr thought the company had applied a double standard in choosing to dismiss her.

BEFORE YOU CLICK AWAY!

December is make or break for us. A full one-third of our annual fundraising comes in this month alone. A strong December means our newsroom is on the beat and reporting at full strength. A weak one means budget cuts and hard choices ahead.

The December 31 deadline is closing in fast. To reach our $400,000 goal, we need readers who’ve never given before to join the ranks of MoJo donors. And we need our steadfast supporters to give again today—any amount.

Managing an independent, nonprofit newsroom is staggeringly hard. There’s no cushion in our budget—no backup revenue, no corporate safety net. We can’t afford to fall short, and we can’t rely on corporations or deep-pocketed interests to fund the fierce, investigative journalism Mother Jones exists to do.

That’s why we need you right now. Please chip in to help close the gap.

BEFORE YOU CLICK AWAY!

December is make or break for us. A full one-third of our annual fundraising comes in this month alone. A strong December means our newsroom is on the beat and reporting at full strength. A weak one means budget cuts and hard choices ahead.

The December 31 deadline is closing in fast. To reach our $400,000 goal, we need readers who’ve never given before to join the ranks of MoJo donors. And we need our steadfast supporters to give again today—any amount.

Managing an independent, nonprofit newsroom is staggeringly hard. There’s no cushion in our budget—no backup revenue, no corporate safety net. We can’t afford to fall short, and we can’t rely on corporations or deep-pocketed interests to fund the fierce, investigative journalism Mother Jones exists to do.

That’s why we need you right now. Please chip in to help close the gap.

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate